UBS Group’s Monopar Therapeutics MNPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $783K | Buy |
21,873
+13,752
| +169% | +$492K | ﹤0.01% | 4527 |
|
|
2025
Q1 | $296K | Buy |
8,121
+1,698
| +26% | +$61.8K | ﹤0.01% | 5038 |
|
|
2024
Q4 | $141K | Buy |
6,423
+5,911
| +1,154% | +$130K | ﹤0.01% | 5462 |
|
|
2024
Q3 | $3.45K | Buy |
+512
| New | +$3.45K | ﹤0.01% | 7052 |
|
|
2024
Q2 | – | Sell |
-514
| Closed | -$1.75K | – | 8614 |
|
|
2024
Q1 | $1.75K | Sell |
514
-1,866
| -78% | -$6.35K | ﹤0.01% | 6886 |
|
|
2023
Q4 | $4.05K | Buy |
2,380
+2,366
| +16,900% | +$4.02K | ﹤0.01% | 6699 |
|
|
2023
Q3 | $45 | Buy |
+14
| New | +$45 | ﹤0.01% | 7875 |
|
|
2023
Q2 | – | Sell |
-1,278
| Closed | -$8.88K | – | 8186 |
|
|
2023
Q1 | $8.88K | Buy |
1,278
+647
| +103% | +$4.5K | ﹤0.01% | 6592 |
|
|
2022
Q4 | $7.48K | Sell |
631
-449
| -42% | -$5.32K | ﹤0.01% | 7697 |
|
|
2022
Q3 | $8K | Sell |
1,080
-2,832
| -72% | -$21K | ﹤0.01% | 7626 |
|
|
2022
Q2 | $45K | Buy |
3,912
+3,291
| +530% | +$37.9K | ﹤0.01% | 4987 |
|
|
2022
Q1 | $8K | Buy |
621
+8
| +1% | +$103 | ﹤0.01% | 7626 |
|
|
2021
Q4 | $10K | Buy |
+613
| New | +$10K | ﹤0.01% | 7664 |
|
|
2021
Q2 | – | Sell |
-114
| Closed | -$4K | – | 8448 |
|
|
2021
Q1 | $4K | Sell |
114
-76
| -40% | -$2.67K | ﹤0.01% | 7379 |
|
|
2020
Q4 | $6K | Buy |
+190
| New | +$6K | ﹤0.01% | 6734 |
|
|
2020
Q2 | – | Sell |
-3
| Closed | – | – | 7214 |
|
|
2020
Q1 | $0 | Sell |
3
-255
| -99% | – | ﹤0.01% | 7128 |
|
|
2019
Q4 | $21K | Buy |
+258
| New | +$21K | ﹤0.01% | 5782 |
|